Generic Latisse Launched Online Worldwide By Universal Generic Drugs
Universal Generic Drugs now launches the age old Generic Latisse worldwide. Universal Generic Drugs, an online pharmacy that deals has recently included the generic version Bimatoprost in its closets.
Online PR News – 29-September-2012 – bartow/FL – Universal Generic Drugs now launches the age old Generic Latisse worldwide. Universal Generic Drugs, an online pharmacy that deals has recently included the generic version Bimatoprost in its closets.
The highly concealed Latisee formulation has been finally revealed and launched as the new version of Generic Latisse (ophthalmic solution). Latisse promotes eyelash growth, as a beauty enhancer has long been approved by the FDA for its commercial production and public use. The drug is used in medical conditions like hypotrichosis or decreased eyelash growth. Bimatoprost is the currently available therapy for the treatment of hypotrichosis, although the drug is a prescription based one. The drug can also be used for conditions like glaucoma to reduce intraocular pressure. Bimatoprost is a time tested and scientifically proven therapy that has been an active ingredient of Latisse. Generic Latisse is the tablet form is being developed and marketed by Watson Pharma, headquartered in the eastern state of Texas, which has a turnaround of $ 243 million in the United States.
It has taken almost 9 years to design and develop the Bimatoprost molecule and the company has tried the drug in 3 phases of clinical trials, which all proved to be effect producing, and the benefits of the drug outweigh its risks. Watson Laboratories had sent in patent applications for bimatoprost ophthalmic solution 0.01% and 0.03%, which work at different levels of therapeutic efficacy. Generic Latisse is also known to produce substantial effects against glaucoma or increased intraocular pressure, and in the future will be used as part of mainstream therapy reducing intraocular pressure n patients with glaucoma.
Latisse generic is considered a safe therapy from a clinical standpoint by the doctors who developed the cokmpound as well as the scientific community who tested them as well as the FDA. Some clinical side effects include a slight darkening of the skin of eyelash, which is reversible and can be taken care without taking any additional drugs. A sensation of itching and growth of hair on other areas where generic latisse may occur, and had to be carefully wiped away. Also there are of decrease or inconsistent eyelash length, which can be easily countered. The use of generic latisse is contraindicated to people using drugs like Lumigan for increasing the intraocular pressure, and it is highly advised to not use the drug on the lower eyelid as it has a higher chance of percolation into the inner surface of lower eyelids.
Although drug discovery and its production are tedious process, we keep the challenges high up our head, which keeps us growing. We currently do not have much competition and are able to deliver more than we say. The price at which Watson chooses to offer the generic drug is yet to be decided by the board members. Shareholders, developers, and people in general are quite happy to know that Latisse is back into the market its generic form and provide relief to millions.